We have previously shown that gp65 (E3) is a virion structural protein which varies widely in quantity among different strains of mouse hepatitis virus (MHV) . In this study, the biosynthetic pathway and possible biological activities of this protein were examined.
The glycosylation of gp65 in virus-infected cells was inhibited by tunicamycin but not by monensin, suggesting that it contains an /V-glycosidic linkage. Glycosylation is cotranslational and appears to be complete before the glycoprotein reaches the Golgi complex. Pulse-chase experiments showed that this protein decreased in size after 30 min of chase, suggesting that the carbohydrate chains of gp65 undergo trimming during its transport across the Golgi. This interpretation is supported by the endoglycosidase treatment of gp65, which showed that the peptide backbone of gp65 did not decrease in size after pulse-chase periods. This maturation pathway is distinct from that of the El or E2 glycoproteins.
Partial endoglycosidase treatment indicated that gp65 contains 9 to 10 carbohydrate side chains; thus, almost all of the potential glycosylation sites of gp65 were glycosylated. In vitro translation studies coupled with protease digestion suggest that gp65 is an integral membrane protein. The presence of gp65 in the virion is correlated with the presence of an acetylesterase activity.
No hemagglutinin activity was detected.
INTRODUCTION
Mouse hepatitis virus (MHV), a member of the Coronaviridae family, is an enveloped virus with a positivesensed RNA genome of more than 6 X lo6 molecular weight (Lai and Stohlman, 1978; Wege et a/., 1978) . The virion particle is composed of three structural proteins: two glycosylated envelope proteins, gpl8OIgp90 (E2) and gp23 (El), and a phosphorylated nucleocapsid protein pp60 (N). The E2 protein forms the spikes on the surface of virion, is responsible for viral interaction with target cells and fusion activity, and also elicits neutralizing antibodies (Sturman and Holmes, 1983) . Monoclonal antibodies against E2 alter the pathogenicityof MHV (Fleming eta/., 1986; Dalziel eta/., 1986) . El is a transmembrane matrix protein (Sturman et al., 1980; Rottier et al., 1984 Rottier et al., , 1986 the function of which is not yet clear. Some monoclonal antibodies against El can also alter the pathogenicity of the virus (Fleming eta/., 1989) . The N protein is a phosphotylated nucleocapsid protein (Stohlman and Lai, 1979) which interacts with virion RNA (Sturman et al., 1980; Baric et al., 1988) . Some strains of MHV, e.g., JHM or MHV-S, contain an additional glycoprotein gp65 (Lai and Stohlman, 1981; Siddell, 1982; Makino et al., 1983) . Since bromelain treatment of JHM virion removed gp65, it has been suggested that this protein is also an envelope ' To whom reprint requests should be addressed.
protein, part of which is exposed on the viral surface of this virus (Makino et al., 1983) . The structural proteins of MHV are translated from virus-specific monocistronic mRNAs in the virus-infected cells (Rottier et al., 198 1; Leibowitz et al., 1982) . These mRNAs have a 3'-coterminal nested-set structure (Lai et a/., 1981; Leibowitz et al., 1981) . Only the 5'-terminal unique region of each mRNA is used for translation (Leibowitz et al., 1982; Siddell, 1983) . The E2 protein is translated from mRNA 3, and glycosylated at asparagine residues via N-glycosidic bonds (Holmes et a/., 1981; Rottier et al., 1981) . It is first synthesized as a ~110 precursor, and glycosylated to gpl50 and then to gpl80 (Siddell et a/., 198 1; Rottier et a/., 1981) . It is subsequently cleaved into two gp90 subunits (Sturman et al., 1985) . This cleavage is required for viral infectivity and is carried out by cellular proteases (Storz et a/., 1981; Yoshikura and Tajima, 1981; Sturman et al., 1985) . In contrast, El protein is an O-linked glycoprotein, which is probably glycosylated in the Golgi complex post-translationally (Holmes et a/., 1981; Niemann and Klenk, 1981; Niemann et al., 1984; Rottier and Rose, 1987) . The glycosylation of the E 1 protein is resistant to tunicamycin but is sensitive to monensin, which acts at the Golgi complex level (Niemann et al., 1982) . In contrast to what is known about El and E2, the biosynthetic pathway of gp65 in MHV-infected cells is not yet clear. Recently we have shown that gp65 is translated from a new mRNA designated mRNA 2b, which is synthesized by only a few isolates of JHM strains of MHV (Makino and Lai, 1989; Shieh et al., 1989) . This mRNA corresponds to an open reading frame (ORF) 2b which encodes gp65 (Shieh et al., 1989) . The unique aspect of this protein is that its expression is variable among different MHV strains and is regulated by the sequences of leader RNA at the 5'end of genomic RNA and the intergenic region preceding the ORF 2b. For instance, JHM(3) virus, which contains three UCUAA repeats at the 3'-end of leader RNA, makes only a small quantity of gp65 (Makino and Lai, 1989; Shieh eta/., 1989) . In contrast, JHM(2) virus with two UCUAA repeats makes an abundant quantity of the protein (Shieh et a/., 1989) . Although the genomic RNA of the A59 strain of MHV contains ORF 2b and two UCUAA repeats, it lacks both correct transcriptional and correct translational start signals for this gene, resulting in the absence of gp65 in A59 virus (Luytjes et al., 1988; Shieh et a/., 1989) .
The gp65 protein has also been detected in another coronavirus, bovine coronavirus (BCV) (King and Brian, 1982) . This protein, termed E3, contains both an esterase activity, which is similar to the receptor-destroying activity of influenza C virus (Vlasak et al., 1988a) , and a hemagglutinin activity (King et a/., 1985) . Significantly, the predicted sequence of gp65 of MHV is homologous to the hemagglutinin protein of influenza C virus (Luytjes et a/., 1988) although hemagglutinin activity has not been demonstrated for MHV (Talbot 1989) . The presence of this protein in certain strains of coronaviruses raises the question whether the added biological activity of this protein contributes to the biological or pathogenic properties of the viruses.
To answer such a question, we characterized the biochemical properties of gp65 of MHV. In this report, we determined its structure, biosynthetic pathway, and esterase activity.
MATERIALS
AND METHODS
Virus and cells
The plaque-cloned JHM(2), which contains two UCUAA repeats at the 3'-end of leader sequence (Makino and Lai, 1989) was used for most of the experiments described in this study. Two other MHV isolates, JHM(3), which contains three UCUAA repeats (Makino and Lai, 1989) and A59 strains were also used. Viruses were propagated on DBT cell, a mouse astrocytoma cell line (Hirano et a/., 1974) according to the methods described previously (Makitio et a/., 1984) .
Preparation of rabbit antiserum specific for JHM(2) virion proteins JHM(2) virus was purified from approximately 1 liter of media from infected DBT cells according to the pub-lished method (Makino et a/., 1983) . Briefly, virus particles were purified by discontinuous and continuous sucrose gradients, pelleted by centrifugation in a Beckman SW41 rotor at 40,000 rpm for 2 hr, and then suspended in TE buffer (0.01 M Tris-HCI, pH 7.4 and 1 mn/r EDTA) containing 0.1 %I SDS. Purity of virus was examined by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and staining with Coomassie blue. The purified virus was injected into rabbits intramuscularly three times with 2-week intervals. The first injection was made with complete Freund's adjuvant, whereas second and third ones were with incomplete adjuvant. After checking the titer of antiviral antibody by ELISA, rabbits were bled. Serum was complement-inactivated at 56" for 30 min, adsorbed with uninfected DBT cells, and filtered before use.
35S-labeling of intracellular proteins and preparation of cell extracts
Confluent monolayers of DBT cells (1.5 X 1 O6 cells) were infected with virus at a multiplicity of infection of 2. After 1 hr adsorption at 37", virus inoculum was replaced with minimum essential media (MEM) containing 5% dialyzed fetal calf serum (FCS). At 8.5 hr postinfection, medium was changed to methionine-free MEM containing 2% dialyzed FCS. After 30-min starvation for methionine, 35S-translabel (1 193 Ci/mmol; ICN Biochemicals) was added to a final concentration of 50 &i/ml. Cells were pulse-labeled for either 20 or 5 min and chased for different periods of time. Cells were then placed on ice, washed three times with cold phosphate-buffered saline (PBS), and lysed with 400 ~1 of lysis buffer (1% Triton X-l 00, 0.5% sodium deoxycholate, and 0.1% SDS in PBS) containing 1 mll/l phenyl methyl sulfonyl fluoride (PMSF). Cell lysate was immediately passed through a 1 g-gauge syringe needle five times and centrifuged at 12,000 g for 10 min at 4". The supernatant fluid was stored at -70". lmmunoprecipitation and SDS-PAGE Each cytoplasmic lysate was incubated with rabbit hyperimmune serum prepared against purified JHM(2) at 4" for 2 hr. Protein A (Pansorbin, Calbiochem) (10% suspension in 0.05% NP-40) was then added to the reaction mixture, which was further incubated at 4'for 2 hr. Precipitates were washed with lysis buffer several times. The final pellet was suspended in 2X sample buffer (0.06 NITris-HCI, 2% SDS, 25% glycerol, 5% 2mercaptoethanol, and 0.1 O/O bromphenol blue), heated at 95" for 3 min, and centrifuged at 12,000 g for 5 min. The supernatants were electrophoresed on 7.5 to 15% gradient polyacrylamide gel containing 0.1% SDS.
Tunicamycin and monensin treatments
At 3 hr postinfection, tunicamycin (Sigma) was added to media to a final concentration of 0.3-l pg/ml. At 8 hr p.i., cells were pulse-labeled in the presence of tunicamycin with 35S-translabel for 20 min and processed for immunoprecipitation as described above. For monensin treatment, monensin (Sigma) was added to the media to a final concentration of 1 Od7 to 1 Oe5 M at 3 hr p.i. At 8 hr p.i., cells were pulse-labeled with 35Stranslabel for 20 min and then chased with cold methionine for 2 hr before immunoprecipitation.
Endoglycosidase H treatment
After immunoprecipitation of infected cell lysates, the immune complexes bound to Pansorbin were eluted by heating in 0.5% SDS and 50 mM Tris-HCI, pH 7.5, at 95" for 4 min (Kakach eta/., 1989) and centrifuged. The supernatant was mixed with an equal volume of 1 M sodium citrate buffer (pH 7.0) containing 1 mM PMSF and 1 to 25 mU of endoglycosidase H (Boehringer-Mannheim) and incubated at 37" for different periods of time ranging from 1 min to 16 hr. After incubation, the reaction mixture was mixed with an equal volume of 2x sample buffer and heated at 95" for 4 min before SDS-PAGE analysis.
In vitro transcription and translation
Recombinant plasmid pT7(2B) (Shieh et a/., 1989) was linearized by digestion with EcoRI or BarnHI and transcribed in vitro with T7 RNA polymerase as previously described (Soe et a/., 1987; Tabor and Richardson, 1985 
Protease digestion
Translation mixtures were diluted 1:2 with 50 mlVI Tris-HCI buffer, pH 7.4, containing 100 ml\/l NaCl and 3 mg/ml Pronase (Sigma), and incubated at 0" for 30 min. Proteolysis was terminated by treatment with a protease-inhibitor cocktail containing 10 mM PMSF, 2.5 mM EDTA, 1.4 mg/ml Pepstatin A, and 3 mg/ml Aprotinin. Samples were analyzed by SDS-PAGE.
Acetylesterase assays
Media collected at 14 hr p.i. from the virus-infected cells were precipitated by ammonium sulfate (Makino et a/., 1984) . Virus precipitates were suspended in PBS, and incubated with 1 mr2/1 p-nitrophenylacetate (Sigma) at room temperature.
Hydrolysis of the substrate was monitored at 400 nm at 2-min intervals as previously described (Vlasak et al., 1988a) , using a chart recorder. Media from mock-infected cells were also precipitated with ammonium sulfate as a control. The background counts of this control were subtracted from those of virus samples. An aliquot of virus precipitate was used for plaque assay to determine virus titers of each virus preparation. The O.D.,,, values of each virus were normalized with respect to the virus titer used.
Hemagglutination assay
Fresh red blood cells from mice (BALB/C and C57BL) were washed and resuspended in PBS to a final concentration of 0.5%, and then aliquoted (50 ~11 into each well) into V-shaped microtiter plates. Equal volumes of a series of twofold dilutions of the different virus preparations were added to each well. Plates were incubated at 4' overnight before results were read.
RESULTS

Detection of intracellular virus-specific gp65
To study the structure, biosynthesis, and possible biological activities of gp65, we first determined the intracellular form of gp65 in cells infected with different strains of MHV, including A59 and two strains of JHM, JHM(2), and JHM (3), which differ in the number of UCUAA repeats in the leader sequence (Makino and Lai, 1989; Shieh et al., 1989) . Cells were pulse-labeled with 35S-translabel for 20 min, immunoprecipitated with antibodies made against JHM(2) virion which contains a large quantity of gp65 (Shieh et a/., 1989) and then analyzed by SDS-PAGE.
As can be seen from Fig. 1 , JHM(2) synthesizes a prominent species of 65-kDa protein in addition to N, El, and E2 proteins. This virus has been shown to synthesize a large amount of mRNA 2b in infected cells (Makino and Lai, 1989; Shieh et a/., 1989) . In contrast, JHM(3), which synthesizes a very small amount of mRNA 2b, synthesized a comparatively smaller quantity of gp65. This is in agreement with the previous finding that mRNA 2b is the mRNA for gp65 (Makino and Lai, 1989; Shieh et a/., 1989) . Surprisingly, A59, which does not synthesize mRNA 2b (Makino and Lai, 1989) and does not contain ORF 2b with an initiator AUG (Luytjes et a/., 1988) also makes a small amount of gp65. Since this protein was precipi- protein was detected. In contrast, the size of gp23(El) was not affected by the presence of tunicamycin, since it is an O-linked glycoprotein (Niemann and Klenk, 1981; Holmes et al., 1981; Rottier and Rose, 1987) . It is interesting to note that the 45-kDa protein detected in the presence of tunicamycin appears to consist of two bands, in agreement with the previous in vitro translation studies of mRNA 2b (Shieh eta/., 1989) . The significance of this finding is unknown at the present time. Another inhibitor of glycoprotein transport, monensin, affected the synthesis of the three viral glycoproteins differently. As shown in Fig. 3 , monensin reduced the size of El. This result is in agreement with the published finding that El glycosylation occurs in Golgi complex (Niemann et a/., 1982; Rottier and Rose, 1987) . In contrast, E2 maturation occurred even in the presence of monensin. However, the size of the mature E2(gp90) was slightly smaller than that of E2 synthesized in the absence of monensin. The two protein bands corresponding to E2 (90K) probably represent different glycosylation states of the protein. This result indicates that the final carbohydrate residues on E2 glycoproteins are added in the Golgi apparatus and that incomplete glycosylation does not interfere with tated with JHM(2)-gp65-monospecific antibodies (data not shown), it is probably related to the JHM-specific gp65. The significance of this protein in A59 will be discussed later.
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--EZ(15010 *E2(11010 The relative amount of gp65 in infected cells is considerably higher than that in virion (Shieh et a/., 1989) suggesting that the incorporation of gp65 into virion is poor.
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Biosynthesis of gp65 in the presence of tunicamycin and monensin To understand the biosynthetic pathway of gp65, we studied the synthesis of viral glycoproteins in JHM (2) virus-infected cells in the presence of different inhibitors of glycosylation. Tunicamycin has been shown to inhibit the synthesis of ALglycosidic bond-linked glycoproteins (Takatsuki et al., 1975) . As shown in Fig. 2 , tunicamycin inhibited the synthesis of gp65. Instead, a protein of 45 kDa was detected. This result is consistent with the previous in vitro translation studies which indicated that the peptide portion of this glycoprotein is of 45 kDa (Shieh eta/., 1989). Furthermore, it demonstrates that gp65 is an N-linked glycoprotein. In agreement with the published data (Niemann and Klenk, 198 l), the glycosylated E2 was not detectable in the presence of tunicamycin. instead, a pl 10 precursor +E1(2lK) the cleavage of gpl80 into gp90. In contrast, the size of gp65 was not affected by the presence of monensin (Fig. 3, lanes 3 and 4) suggesting that the glycosylation of gp65 was completed before the protein was transported into Golgi complex. Careful examination of Fig. 3 also revealed that, after 2 hr of chase with cold methionine, gp65 slightly decreased in size ( fig. 3 , lanes 2 and-3) suggesting that further processing of gp65 takes place after its glycosylation (see also Fig. 4 ). Monensin did not affect this processing (Fig. 3, lane 4) .
Pulse-chase studies of g.p65 biosynthesis
To further study the biosynthetic pathway of gp65, additional pulse-chase experiments were carried out. Figure 4 shows that a fully glycosylated gp65 could be detected after 5 min of pulse-labeling. No precursor 45-kDa protein could be detected, even after pulse-labeling for as short as 2 min (data not shown). This result suggests that glycosylation of gp65 may be cotranslational. After 30 min of chase, a slight decrease of gp65 size was noticeable (Fig. 4, lane 4) . The size reduction of gp65 reached a maximum after 1 hr of chase (lane 5). These kinetics of gp65 processing suggest that a trimming of carbohydrate or peptide of gp65 occurred in the Golgi complex (Johnson and Spear, 1983) . In contrast, El was not glycosylated during the 5-min pulse-labeling period. The glycosylation of El did not begin to occur until after 30 min of chase period. The fully glycosylated El could not be detected until after 2 hr of chase. This result is consistent with the monensin studies which suggest that the glycosylation of El occurs in the Golgi complex. The glycosylation of E2 occurred rapidly during the 5-min pulse-labeling period, resulting in the detection of gpl50. The cleaved E2 (gp90) could not be observed until after 1 hr of chase period. Thus, the final glycosylation of E2 probably also occurred in the Golgi complex.
Removal of carbohydrates by endoglycosidase treatments
To determine whether the decrease in the size of gp65 during chase period is because of trimming of carbohydrate or cleavage of peptide backbone, we treated the intracellular viral glycoproteins with either endoglycosidase H or endoglycosidase F to remove carbohydrate side chains. As shown in Fig. 5 , the endo H treatment reduced gp65 to a size of 45 kDa, indicating that most of the carbohydrate side chains have been removed. The sizes of endo H-treated gp65 were identical between samples chased for 10 and 60 min, even though the untreated gp65 at these two time points differed in size. This result suggests that the decrease in the size of gp65 during the chase period is because of trimming of carbohydrate side chains. It is also noted that two proteins of approximately 45 kDa were detected after endo H treatment. Prolonged treatment (16 hr) and higher endo H concentration (25 mu) did not eliminate either of these two proteins (data not shown). Thus, these two proteins were not the result of incomplete endo H treatment. Similar results were obtained after treatments with endoglycosidase F (data not shown). The significance of these two proteins will be discussed later.
It has previously been determined that gp65 of JHM contains 10 potential N-glycosylation sites (Shieh eta/., 1989) . To determine the actual number of carbohydrate side chains in this protein, we treated gp65 with endoglycosidase H under very mild conditions to achieve partial and stepwise removal of carbohydrate side chains. As shown in Fig. 6 , at least 9 or 10 distinct protein species could be detected, ranging from the complete gp65 to the final digestion products. These products most likely represent the intermediates of endo H-digestion products. This result suggests that most, if not all, of the potential IV-glycosylation sites are glycosylated.
Topology of gp65 in the membrane
Since gp65 contains hydrophobic domains at both N-and C-termini (Shieh er al., 1989) it is very likely an integral membrane protein. To determine the likely topology of gp65 in the membrane, we performed in vitro translation of the ORF 2b RNA transcribed from a pT7 plasmid construct.
Translation was performed in the presence of canine pancreatic microsomal membranes, and translation products were digested with Pronase to remove the portion of proteins not translocated into the lumen of microsomal membranes. As shown in Fig. 7 , in vitro translation of this RNA yielded a primary translation product of 45 kDa, which was glycosylated to a protein of 65 kDa in the presence of microsomal membranes. The latter protein was converted to a protein of 35 kDa after Pronase digestion. This result suggests that gp65 is indeed a membrane protein with roughly a 35-kDa portion protruding into the lumen of microsomal membrane. Translation of a truncated RNA representing the 5'-end 768 nucleotides of ORF 2b resulted in a primary translation product of 28 kDa which corresponds to the N-terminal portion of gp65. In the presence of microsomal membrane, this protein was converted to a protein of 33 kDa. Thus, the N-terminal portion alone of gp65 has the capacity to be translocated across the membrane.
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FIG. 5. Endoglycosidase H treatment of intracellular viral glycoproteins. JHM(2)-infected cells were pulse-labeled with "S-translabel for 5 min and chased for 10 min or 1 hr. Lysates were immunoprecipitated, dissolved in 50 mM Tris-HCI (pH 7.4) containing 0.5% SDS, and boiled for 4 min before endoglycosidase H treatment (3 mu, at 37" for 16 hr). Lane 1, 5-min pulse, 1 0-min chase, endoglycosidase H (3 mu); lane 2, 5-min pulse, 1 0-min chase, no endoglycosidase H treatment; lane 3, 5-min pulse, I-hr chase, endoglycosidase H (3 mu); lane 4, 5-min pulse, 1-hr chase, no endoglycosidase H treatment: M, %protein molecular weight markers.
Esterase and hemagglutinin activities of gp65
The gp65 (E3) of BCV has been shown to contain both hemagglutinin (King et al., 1985; Parker et a/., 1989) and esterase activities (Vlasak et a/., 1988a). We therefore determined whether gp65 of MHV also contains similar activities. We purified JHM(2), JHM(3), and A59, which contain different amounts of gp65 in the virion, and tested the presence of esterase activities, using p-nitrophenylacetate as a substrate. Figure 8 shows that, although both JHM strains could hydrolyze p-nitrophenylacetate, JHM(2) has a considerably higher activity. Since the only difference among these three viruses in virion structural proteins is the amount of gp65 (Fig. 1) (Shieh eta/., 1989) this result is consistent with gp65 being responsible for the esterase activity. A59 has a very low but detectable esterase activity, consistent with the presence of a trace amount of gp65 in the virion.
We have also tested the possible presence of a hemagglutinin activity of these three strains of MHV, using red blood cells from several different animal species, including mouse, sheep, chicken, bovine, guinea pig, rat, and human. While BCV was demonstrated to hemagglutinate all of these red blood cells, none of the MHV strains tested agglutinated these cells (data not shown). Thus, MHV gp65 does not possess hemagglutinin activities detectable under these conditions. 
DISCUSSION
gp6.5 (E3) is an optional structural protein among coronaviruses.
It has been detected in BCV (King et al., 1985) , human coronavirus OC43 (Hogue and Brian, 1986) , and turkey coronavirus (Dea and Tijssen, 1988) and is absent in avian infectious bronchitis virus (IBV) (Cavanagh, 1981) . The best characterized gp65 is the one in BCV. It is a membrane glycoprotein, which forms short spikes on virion surface (King et a/., 1985) . It contains hemagglutinin (King et a/., 1985; Parker et al., 1989) and esterase activities (Vlasak et al., 1988a) . Some strains of MHV also contain gp65 (Lai and Stohlman, 1981; Siddell, 1982; Makino et al., 1983) . Even within a particular strain, e.g., JHM, the amount of gp65 appeared to be variable with different virus stocks. Because of this variability and because no known viral genes or mRNAs were capable of encoding this protein, the identity of this glycoprotein in MHV has long been in question. Recently, our laboratory has identified a genetic region in MHV genome capable of encoding gp65 (Shieh eta/., 1989) . Furthermore, we have determined the molecular basis of differential transcription of this gene in different MHV strains (Makino and Lai, 1989; Shieh et al., 1989) . Thus, this glycoprotein is an optional protein among MHVs. However, our current study showed that even A59 strain, which does not have a complete gene 2b (Luytjes eta/., 1988) , synthesizes a small amount of gp65 (Shieh et a/., 1989) . Therefore, this protein may possibly be indispensable for MHV.
The data presented in this report provide information on the biosynthetic pathway of gp65 and also addi-tional details on the biosynthesis of El and E2. It is interesting that the three glycoproteins of MHV have different biosynthetic pathways.
El is glycosylated via an 0glycosidic
bond (Holmes et al., 1981; Niemann and Klenk, 1981) and is thus resistant to tunicamycin (Fig. 2) . Our studies also suggest that its glycosylation occurs entirely within the Golgi complex. This conclusion is supported by the findings in this report that the glycosylation of El was inhibited by monensin, which interferes with protein transport in Golgi complex, and that glycosylation of El took nearly 2 hr to complete (Fig. 4) , which is the length of time required for protein transport across Golgi. In contrast, E2 is glycosylated via an N-glycosidic bond, which occurs probably cotranslationally (Niemann et al., 1982) . Our study also showed that the final step of glycosylation of E2 occurs within Golgi complex, since monensin treatment reduced the size of E2 (gp90), which was not detected until after 1 hr of chase period (Fig. 4) . The data in this study suggest that gp65 is also glycosylated cotranslationally via an N-glycosidic bond. However, the glycosylation of gp65 is completed before the protein reaches cis-Golgi. This conclusion is supported by the findings that monensin did not affect the size of gp65 and that a full-length gp65 was detectable after only 5 min of labeling (Fig. 4) tional dichotomy during the evolution of viruses is interesting. Probably because of the hemagglutinin activity of gp65, BCV has been found to share the same receptor as influenza C virus (Vlasak eta/., 1988b) . The esterase activity of BCV is also similar to the receptor-destroying enzyme of influenza C virus (Vlasak et al., 1988a) . The presence of gp65 in MHV may alter the tissue tropism, antigenicity, and pathogenicity of virus. Such a possibility is currently being studied. The background counts of the mock-infected control media were subtrated from those of virus samples. The experiment was duplicated and average was taken.
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This work was supported by U.S. Public Health Services Research Grants Al 19244 and NS 18146 and National Multiple Sclerosis Society Grant RG 1449. NLM is a postdoctoral fellow of the National Multiple Sclerosis Society. experiment showed that gp65 underwent a trimming of carbohydrate chains during its transport across Golgi and that the trimming was not inhibited by monensin. This carbohydrate trimming is not observed with either El or E2. Thus, the maturation processes of the three glycoproteins of MHV appear to be different from each other.
The detection of probably two unglycosylated precursor proteins of gp65 is of considerable interest. These two protein species were seen in the in vitro translation products of purified mRNA 2b (Shieh el al., 1989) , in the precursor proteins accumulated in the presence of tunicamycin (Fig. 2) , and in the endoglycosidase H-or endoglycosidase F-treated protein (Fig.   5 ). However, only one protein was detected in the in vitro translation product of ORF 2b RNA (Shieh et al., 1989) . These results suggest that there might be two different mRNA 2b species in JHM(2)-infected cells. We have examined three different isolates of JHM(2), all of which exhibited this heterogeneity of gp65 (data not shown). Thus, this heterogeneity is probably not caused by heterogeneity of virus population, but rather is the result of mRNA heterogeneity, which could be derived from alternative initiation or possible RNA editing. The latter mechanism has been suggested from studies of P gene of paramyxoviruses (Thomas et al., 1988) . This possibility is particularly tempting since A59, which does not have a functional ORF 2b because of the lack of an initiator AUG (Luytjes et al., 1988) and does not have a consensus transcriptional initiation sequence (Shieh et a/., 1989), also synthesizes a small amount of gp65 (Fig. 1) . The origin of gp65 in A59 strain and of gp65 heterogeneity in JHM strain is currently under study in our laboratory.
Similar to BCV, the gp65 of JHM strain also contains an esterase activity. However, no hemagglutinin activity was detected, in contrast to gp65 of BCV. This func-
